Data To Be Submitted in Q4 For Approval
Two Phase III studies with combination drug showed clinically significant improvements in lung function
Rayno Life Science Pick and Deja Vu Trade
Last April at the same BIO Conference we wrote about Phase II data from Vertex when biopharmaceutical stocks got a‘Turbo Boost “from Vertex.The stock soared 58% to $82 at that time.
Vertex was added to the Rayno Life Science Portfolio on 11/15/13 at a price of $62.8.
(Posting from BIO)
Mid Day Market Update-Biotech Stocks 1:15p EDT
ETFs FBT up 2.26%, IBB up 1.9%, XBI up 0.66%
Usual Suspect Movers: CLVS up 2.78%, EPZM up 3.46%, ICPT up 2.88%, JAZZ down 2.11%,PBYI up 2.4%, SRPT down 3%. Small caps lagging.
Index of 50 mid and small cap biopharmaceuticals up 0.8%.
Tired Tape Tempers Traders (after close)
Watch market closely tomorrow as energy stocks were surprisingly weak today with the XLE down 2% DJ Transportation averages down 0..85%, basic materials down 1.3% and industrials were down 1%. Iraq worries have come back to center stage.